6,037 reports of this reaction
1.4% of all QUETIAPINE reports
#20 most reported adverse reaction
DRUG DOSE OMISSION is the #20 most commonly reported adverse reaction for QUETIAPINE, manufactured by H2-Pharma, LLC. There are 6,037 FDA adverse event reports linking QUETIAPINE to DRUG DOSE OMISSION. This represents approximately 1.4% of all 427,224 adverse event reports for this drug.
QUETIAPINE has an overall safety score of 85 out of 100. Patients taking QUETIAPINE who experience drug dose omission should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG DOSE OMISSION is a less commonly reported adverse event for QUETIAPINE, but still significant enough to appear in the safety profile.
In addition to drug dose omission, the following adverse reactions have been reported for QUETIAPINE:
The following drugs have also been linked to drug dose omission in FDA adverse event reports:
DRUG DOSE OMISSION has been reported as an adverse event in 6,037 FDA reports for QUETIAPINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG DOSE OMISSION accounts for approximately 1.4% of all adverse event reports for QUETIAPINE, making it a notable side effect.
If you experience drug dose omission while taking QUETIAPINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.